Evidence map›Paper›PMID 41423272›Full record

ArticleJournal for immunotherapy of cancer2025

Clinical and molecular characterization of

Karam Ashouri, Joshua Millstein, Yan Yang, Joanne Xiu, Shivani Soni, Pooja Mittal, Sandra Algaze, Lesly Torres-Gonzalez, Priya Jayachandran, Wu Zhang and 13 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. AXL signaling in cancer: from molecular insights to targeted therapies.Signal transduction and targeted therapy · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Karam AshouriDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.ORCID http://orcid.org/0009-0000-1825-1033
Joshua MillsteinDepartment of Population and Public Health Sciences, University of Southern California Department of Population and Public Health Sciences, Los Angeles, California, USA.
Yan YangDepartment of Population and Public Health Sciences, University of Southern California Department of Population and Public Health Sciences, Los Angeles, California, USA.
Joanne XiuCaris Life Sciences Phoenix, Phoenix, Arizona, USA.
Shivani SoniDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Pooja MittalDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Sandra AlgazeDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.ORCID http://orcid.org/0000-0001-7233-5019
Lesly Torres-GonzalezDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Priya JayachandranDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Wu ZhangDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Shannon MumenthalerDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.
Anthony F ShieldsDepartment of Oncology, Karmanos Cancer Center, Detroit, Michigan, USA.
Richard GoldbergWest Virginia University Cancer Institute, Morgantown, West Virginia, USA.
Emil LouDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota, USA.ORCID http://orcid.org/0000-0002-1607-1386
Benjamin A WeinbergRuesch Center for The Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
Thomas G GraeberDepartment of Molecular and Medical Pharmacology, University of California Los Angeles, Los Angeles, California, USA.
John L MarshallRuesch Center for The Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Lombardi Comprehensive Cancer Center, Washington, District of Columbia, USA.
Alan P VenookDepartment of Oncology, University of California San Francisco, San Francisco, California, USA.
Alexander HoffmannDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles, Los Angeles, California, USA.
Stacey D FinleyDepartment of Biomedical Engineering, University of Southern California, Los Angeles, California, USA.
Aaron S MeyerDepartment of Bioengineering, University of California Los Angeles, Los Angeles, California, USA.
Francesca BattaglinDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA.ORCID http://orcid.org/0000-0002-9869-0163
Heinz-Josef LenzDivision of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California, USA lenz@med.usc.edu.ORCID http://orcid.org/0000-0003-2178-9568

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Fumito Ito · 1985 to 2026
$181.4M
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
OSU as a Network Lead Academic Participating Site for the NCI NCTNUG1CA233331 · NCI · OHIO STATE UNIVERSITY · PI John L. Hays, Dwight H. Owen · 2019 to 2026
$8.9M
National Capital Area (NCA) NCI Community Oncology Research Program (NCORP)UG1CA239758 · NCI · GEORGETOWN UNIVERSITY · PI Lucile L. Adams-Campbell, Chiranjeev Dash · 2019 to 2026
$6.3M
NCI National Clinical Trials Network – Network Lead Academic Participating SiteUG1CA233163 · NCI · WAYNE STATE UNIVERSITY · PI FLAHERTY, LAWRENCE E, SHIELDS, ANTHONY FRANK · 2019 to 2025
$3.5M
UNC Lead Academic Participating SiteUG1CA233373 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CAREY, LISA A, DEES, ELIZABETH CLAIRE · 2019 to 2025
$3.5M
NCI NIH HHS P30 CA014089NCI NIH HHS P50 CA211015NCI NIH HHS U10 CA180821NCI NIH HHS U10 CA180882NCI NIH HHS U10 CA180888NCI NIH HHS UG1 CA233163NCI NIH HHS UG1 CA233331NCI NIH HHS UG1 CA233373NCI NIH HHS UG1 CA239758
6 · The paper itself

Abstract

background

methodsThis study integrated real-world molecular profiling (Caris cohort; n=24,257) and randomized clinical trial data (phase III Cancer and Leukemia Group B/Southwest Oncology Group (CALGB/SWOG) 80405; n=433) to assess

resultsElevated

conclusionsElevated

Indexed as

Biomarkers, TumorColorectal NeoplasmsProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesAdultAgedAxl Receptor Tyrosine KinaseFemaleHumansMaleMiddle AgedTumor MicroenvironmentAXL protein, humanAxl Receptor Tyrosine KinaseBiomarkers, TumorProto-Oncogene ProteinsReceptor Protein-Tyrosine KinasesBiomarkerColorectal CancerImmune Checkpoint InhibitorsImmunotherapy

Identifiers

PMID41423272
PMCPMC12719898

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.